Mydecine Innovations Group (DB:0NF0) - Prezzo delle azioni, notizie e analisi

0NF0 Panoramica delle azioni

0NF0 analisi fondamentale
Punteggio fiocco di neve
Valutazione	0/6
Crescita futura	0/6
Prestazioni passate	0/6
Salute finanziaria	0/6
Dividendi	0/6

Premi

Gli utili sono cresciuti del 8.7% all'anno negli ultimi 5 anni

Analisi del rischio

Realizza un fatturato inferiore a 1 milione di dollari ( CA$0 )

Non ha una capitalizzazione di mercato significativa ( €333K )

Ha meno di 1 anno di pista di cassa

Patrimonio netto negativo

+ 2 più rischi

Mydecine Innovations Group Inc. Concorrenti

Biofrontera

XTRA:B8FK

€15.4m

SynBiotic

DUSE:SBX

€27.9m

MPH Health Care

DB:93M1

€101.9m

Redx Pharma

DB:0RX

€65.0m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Mydecine Innovations Group
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$0.0035
Massimo di 52 settimane	US$0.076
Minimo di 52 settimane	US$0.0005
Beta	2.77
1Variazione di 1 mese	16.67%
Variazione a 3 mesi	-76.67%
Variazione di 1 anno	-95.33%
3Variazione a 3 anni	-99.94%
Variazione a 5 anni	n/a
Variazione dall'IPO	-100.00%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	0NF0	DE Pharmaceuticals	DE Mercato
7D	16.7%	1.2%	1.3%
1Y	-95.3%	-19.7%	7.9%

Ritorno vs Industria: 0NF0 ha avuto una performance inferiore rispetto al German Pharmaceuticals che ha registrato un rendimento -19.7 % nell'ultimo anno.

Rendimento vs Mercato: 0NF0 ha avuto una performance inferiore al mercato German che ha registrato un rendimento 7.9 % nell'ultimo anno.

Volatilità dei prezzi

Is 0NF0's price volatile compared to industry and market?
0NF0 volatility
0NF0 Average Weekly Movement	120.6%
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

Prezzo delle azioni stabile: Il prezzo delle azioni di 0NF0 è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale di 0NF0 è diminuita da 633% a 121% nell'ultimo anno, ma è comunque superiore al 75% delle azioni German.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2013	3	Josh Bartch	www.mydecine.com

Mydecine Innovations Group Inc. è una società di biotecnologie che si occupa di ricerca, sviluppo e commercializzazione di prodotti a base di psilocibina per il trattamento di patologie mentali. L'azienda si concentra principalmente sul trattamento della dipendenza da nicotina e del disturbo da stress post-traumatico. I suoi principali prodotti candidati includono MYCO-005.

Mydecine Innovations Group Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Mydecine Innovations Group con la sua capitalizzazione di mercato?
0NF0 statistiche fondamentali
Capitalizzazione di mercato	€315.97k
Guadagni(TTM)	-€8.43m
Ricavi(TTM)	n/a

0.0x

Rapporto P/S

0.0x

Rapporto P/E

0NF0 è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
0NF0 Conto economico (TTM)
Ricavi	CA$0
Costo del fatturato	CA$0
Profitto lordo	CA$0
Altre spese	CA$12.46m
Guadagni	-CA$12.46m

Ultimi guadagni dichiarati

Sep 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	-0.20
Margine lordo	0.00%
Margine di profitto netto	0.00%
Rapporto debito/patrimonio netto	-37.4%

Come si è comportato 0NF0 nel lungo periodo?

Vedi performance storica e confronto

0NF0 Panoramica delle azioni

Premi

Analisi del rischio

Mydecine Innovations Group Inc. Concorrenti

XTRA:B8FK

€15.4m

DUSE:SBX

€27.9m

DB:93M1

€101.9m

DB:0RX

€65.0m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

New major risk - Financial position

New minor risk - Financial data availability

Mydecine Innovations Group Inc., Annual General Meeting, Jul 05, 2024

Mydecine Innovations Group Inc. announced that it expects to receive CAD 1 million in funding

Mydecine Innovations Group Inc Announces Resignation of Neil Stevenson-Moore as Director

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 1.104 million.

Recent updates

New major risk - Financial position

New minor risk - Financial data availability

Mydecine Innovations Group Inc., Annual General Meeting, Jul 05, 2024

Mydecine Innovations Group Inc. announced that it expects to receive CAD 1 million in funding

Mydecine Innovations Group Inc Announces Resignation of Neil Stevenson-Moore as Director

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 1.104 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 3.75 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 3.75 million.

Mydecine Innovations Group Inc. Appoints John Ross as Corporate Secretary

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 5 million.

Mydecine Innovations Group Inc., Annual General Meeting, Apr 20, 2023

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 5 million.

Pangenomic Health Inc. (CNSX:NARA) completed the acquisition of Mindleap Health Inc. from Mydecine Innovations Group Inc. (OTCPK:MYCO.F).

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 4.5 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 0.5 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 0.5 million.

Less than half of directors are independent

Mydecine Innovations Group Inc. Announces Appointment of John Ross as Its Chief Financial Officer

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering.

Pangenomic Health Inc. (CNSX:NARA) signed an arm's length non binding Letter of Intent to acquire Mindleap Health Inc. from Mydecine Innovations Group Inc. (OTCPK:MYCO.F) for CAD 4 million.

Mydecine Innovations Group Inc. Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting Mdma Analogs

Mydecine Innovations Group Announces CFO Changes

Mydecine Innovations Group Inc. Announces Resignation of Directors

Mydecine Files Full Patent Application Covering Myco-006 Family of Novel Short-Acting Mdma Analogs

Mydecine Innovations Group Announces U.S. FDA Clears MYCO-001 for Multi-Site Government Funded Trial in Smoking Cessation

Mydecine Innovations Group Inc. Announces Board Changes

Mydecine Innovations Group Inc. has completed a Composite Units Offering in the amount of CAD 4 million.

Mydecine Innovations Group Inc. has completed a Composite Units Offering.

First quarter 2022 earnings released: CA$1.20 loss per share (vs CA$1.25 loss in 1Q 2021)

High number of new and inexperienced directors

Mydecine Innovations Group Inc., Annual General Meeting, May 26, 2022

Full year 2021 earnings released

Mydecine Innovations Group Inc. Reports Positive Pre-IND Meeting with FDA for MYCO-001 Smoking Cessation Study

Mydecine Announces MYCO-005 Family of Improved Safety Microdose Novel Molecules

Mydecine Innovations Group Inc. to Launch Special Access Support and Supply Program in Canada Expanding Access to Psychedelic- Assisted Psychotherapy for Patients

Mydecine Innovations Group Inc. Submits Pre-Investigational New Drug Briefing Package to the FDA for MYCO-001 Seamless Phase 2/3 Smoking Cessation Clinical Trial

Mydecine Innovations Group Inc. Achieves Innovative Supercomputing Artificial Intelligence Modeling in Psychedelic Drug Development Enabling Quick Screening of Billions of Compounds

Mydecine Innovations Group Inc. announced that it expects to receive CAD 5.5 million in funding

Mydecine Files Full Patent Application Covering Multiple Families of Psilocin Analogs

Third quarter 2021 earnings released: CA$0.019 loss per share (vs CA$0.11 loss in 3Q 2020)

Mydecine Innovations Group Files MYCO-003 Final Patent Application and Reports Positive Preclinical Data

Second quarter 2021 earnings released: CA$0.016 loss per share (vs CA$0.046 loss in 2Q 2020)

Mydecine Provides Business Update

Mydecine Innovations Group Expands Portfolio of Novel Molecules Filing New Patent for MDMA-Like Compounds

Mydecine Selects Substance Use Disorder and Smoking Cessation for Novel Psychedelic Molecule MYCO-004

Mydecine Unveils Artificial Intelligence Drug Discovery Program

Mydecine Innovations Group Discovers over 40 Groundbreaking Potential Pharmacologically Active Novel Compounds in Mushrooms

Health Canada Approves Expansion of Mydecine's Cultivation Capabilities for Psilocybin Producing Mushrooms

Health Canada Approves Expansion of Mydecine’s Cultivation Capabilities for Psilocybin Producing Mushrooms

First quarter 2021 earnings released: CA$0.025 loss per share (vs CA$0.006 loss in 1Q 2020)

Mydecine Innovations Group Announces Management Changes

Mydecine Fully Completes the First-Ever International Export of Psilocybin Mushrooms and Solidifies Its Clinical and Commercial Supply Chain

Mydecine Announces Exclusive Partnership and Increased Capabilities with Applied Pharmaceutical Innovation (API) at the University of Alberta

Chief Compliance Officer ? recently sold €783k worth of stock

Mydecine Innovations Group Inc. has completed a Composite Units Offering in the amount of CAD 15 million.

Mydecine Innovations Group Announces Management Changes

Mydecine Innovations Group Appoints Gordon Neal to Board of Directors

Mydecine Innovations Group Announces the Filing of Seven Provisional Patent Applications with the United States Patent and Trademark Office

Mydecine Innovations Group Engages the ProPharma Group to Proceed with FDA Filings and Approval for Novel Research and Multiple Phase Clinical Trials